Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273968 | 0.91 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3280340 | 0.90 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2MAPT | |
| SCHEMBL3274046 | 0.89 | NPC1 (0.49) | GSK3BCYP2D6CYP1A2NPC1MAPT | |
| SCHEMBL3275516 | 0.86 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3278108 | 0.85 | GSK3B (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3274817 | 0.85 | NPC1 (0.47) | GSK3BCYP2D6CYP1A2NPC1MAPT | |
| SCHEMBL3273819 | 0.85 | GAA (0.53) | GSK3BCYP2D6CYP1A2NPC1RAB9A | |
| SCHEMBL3274431 | 0.84 | NPSR1 (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3274308 | 0.84 | HTR4 (0.48) | GSK3BCYP2D6CYP1A2RAB9A | |
| SCHEMBL3275205 | 0.84 | GSK3B (0.41) | GSK3BCYP2D6CYP1A2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | claimed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, HPRT1, XDH | GSK3B 3294/4885CYP2D6 78/4885CYP1A2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.